| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_19795e2a805a1ba7555c5df86c829147 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3084
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-577
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate |
2006-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_204c89f91bb29227ef87800b2c26fd17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9c4133f0ad5c822854fa5b471472e335
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_489db5a3e012776ba853584fc127ac1b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21643d3dc6cbb58e9f5b2ec0e9e2ff8e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6a9a79e56359686df82dedb7bbfcb3eb |
| publicationDate |
2008-04-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
FR-2906808-A1 |
| titleOfInvention |
USE OF MONOCLONAL ANTIBODIES SPECIFIC TO THE O-ACETYLATED FORMS OF GANGLIOSIDE GD2 IN THE TREATMENT OF CERTAIN CANCERS |
| abstract |
The invention relates to artificially modified monoclonal antibodies recognizing only the O-acetylated form of ganglioside GD2, or fragment thereof, said antibody or fragment recognizing O-acetylated GD2 molecules expressed by tumor cells and not recognizing the GD2 molecules expressed on the surface of peripheral nerves, and the use of these antibodies for the treatment and diagnosis of cancers whose cells express O-acetylated GD2. The invention also relates to the use of the 8B6 antibody for the treatment and diagnosis of such cancers. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10745489-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2702428-C2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11697689-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10000575-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014177271-A1 |
| priorityDate |
2006-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |